

MedLife ended 2021 with a consolidated pro-forma turnover of 332 million euros, an increase of 51.6% compared to 2020

"There is a period of active consolidation at the group level. We have an investment budget of about 120 million euros in M&A and organic development at national and regional level "

- *Despite a difficult social and economic context impacted by the second pandemic year, MedLife has managed to become the first Romanian medical services company to reach the threshold of one third of a billion euros*
- *Beyond financial performance and improving profitability, MedLife has continued to play a key role in society through its active involvement in the area of pandemic research and monitoring. The efforts will be intensified, the company will carry out research projects in the area of oncology*
- *MedLife will continue to strongly strengthen its national leadership position through M&A projects and organic development and, as opportunities arise, the company wants to actively invest in the market in the region;*
- *"Despite geopolitical challenges, we believe in Romania". Thus, MedLife is in discussions with 2-3 large and medium-sized companies, but also with 5 other small companies to join the group and aims that most of these discussions will materialize this year.*
- *The development plans for this year also aim at completing the first stage for MedLife Park project, consolidating the radiotherapy and oncology network at country level, as well as the continuous technologicalization of the group units.*

Bucharest, February 25, 2022 - MedLife Group, the leader of the Romanian medical services market, announces last year's financial results. In 2021, the company registered pro-forma consolidated turnover of 1,632 million lei (332 million euros) with 51.6% higher than in 2020 and an almost two folded net profit, amounting to RON 123 million, increasing by 93%. Operating revenues amounted to RON 1,647 million, up 51.6% compared to 2020, while operating expenses reached RON 1,460 million, up 49.4%.

In 2021, MedLife Group continued its dynamic strategy of expansion through acquisitions, and investments were directed towards supporting strategic objectives aimed at research, strengthening the area of radiotherapy and oncology, amplifying the process of digitization and territorial expansion, the budget invested last year exceeding 30 million euros. According to the company's representatives, all business lines followed an upward trend in 2021, with notable performances for the division of laboratories, clinics, hospitals, but also for dentistry and pharmacies. Overall, last year, MedLife's activity had a strong impact at the level of the entire medical system in Romania, with no less than 14 million services being offered nationwide for analysis, investigation, diagnosis, treatment and surgery.

From the perspective of the second year of the pandemic, MedLife focused on quick access to medical interventions for chronic and acute patients in the context of limiting activity in state hospitals. Intense activity was recorded also in the outpatient line of business related to monitoring of chronic pathologies and patients who went through Covid. In this context, the activity of the corporate division was consistent and dynamic, being focused on the support offered to large companies, SMEs and start-ups for the safety

and health of employees during the pandemic. In parallel, the research area has played an important role in the last year, aggregating own resources and additional investments of over 1 million euros.

2021 also marked the consolidation of the oncology services segment after the Group has recently received the Competition Council approval for the acquisition of 50% of the shares of Neolife Romania, the largest transaction carried out by MedLife last year. In addition to its partnership with NeoLife, MedLife announced 7 more transactions last year: Veridia (March 2021), Medica Sibiu (May 2021), CED Pharma (July 2021), Pharmachem Distribution (August 2021), Stomestet Group (November 2021), Oradent (December 2021), Irina Medical Center Galați.

"We have reached a level of maturity that confirms that MedLife is a sustainable and replicable business model, a performance recognized by the recent inclusion of the company in FTSE Russell indices."

We are enthusiastic that we have completed the partnership with NeoLife Romania, being the 36th transaction successfully completed at group level. We currently have discussions in advanced stages for 3 large transactions and another 5 small ones and we aim to complete by the end of this year. In fact, the investment budget planned for the next period is 100-120 million euros and we intend to allocate approximately 50-70 million euros for transactions in Romania and in the countries in the region", said Mihai Marcu, President and CEO of MedLife Group.

The development and expansion plan for 2022 follows the route Cluj-Napoca, Timișoara, Constanța, openings of new clinics in Muntenia and Transilvania, but also in other regions of the country, with the aim of consolidating the national coverage in the next 2 years. At this moment, MedLife has the largest network in Romania, with presence in over 25 large and medium-sized cities in the country, being the only private medical provider with such coverage at national level. In 2022, the development of Sfânta Maria network will be intensified, the second brand of MedLife Group, with a focus on patients who especially want to access NHIH services. This year, Sfânta Maria brand will expand its presence in several small and medium-sized cities, both organically and through acquisitions.

2022 goals are also linked to MedLife Park, the largest medical hub in the country that has entered a steady pace of development. Thus, for this year, the completion of the first stage is planned, which involves the inauguration of a new large outpatient unit, the arrangement of avant-garde green spaces, but also the expansion of the laboratory of molecular biology and pathological anatomy. The company aims for a much larger unit to accommodate the research division that will expand its activity in the oncology area this year. The second stage of development of this medical hub is planned for 2023 when MedLife intends to put into operation new surgery rooms and expand the hospitalization capacity of the largest hospital in the group with another 150 beds. According to the company's representatives, MedLife Park pilot project will be replicated in the medium and long term in several large cities in the country such as Brasov, Sibiu, Cluj or Arad.

In addition to M&A and organic development projects, MedLife will continue to focus on digitization, being a strategic direction for the group's future development. *"As technology advances, the implications for medicine are becoming more apparent: digital consumption is reconfiguring traditional consumer approaches, a new type of patient is emerging who wants to be informed and who wants to have access to applications and devices that make their experience more efficient in terms of time and costs, and as a result of these changes, the medical services market is also changing. The pandemic acted as a catalyst to reimagine the future of health both collectively and personally, and as such we made a much faster leap. If in the first year of Covid we found quick solutions to offer our patients online consultations or we put robots for self-check in and self-pay, in 2021 we focused on digitizing the patient experience in relation to the interaction we have. At the B2C level, we have invested in new tools that help you access anytime and anywhere your entire medical history and even the ability to see them in dynamics or buy products from the shop section - all available in a single app. On the B2B side, we have invested in new digital products*

SISTEMUL MEDICAL



that help us in this interaction with the employer, but also with the employee. In addition, we have digitized a lot of internal streams and programs.

The evolution of technology pushes us to exceed our limits and support increasingly complex actions both medically and technologically. Tomorrow's medicine is about robots, virtual reality, augmented reality, hologram, data processing and remote monitoring - through the investments we make we keep up with technology and, at the same time, bring the medicine of the future closer to the patient", said Mihai Marcu.